|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
|
US6056957A
(en)
*
|
1994-08-04 |
2000-05-02 |
Schering Corporation |
Humanized monoclonal antibodies against human interleukin-5
|
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
AU2004245038A1
(en)
|
2003-06-02 |
2004-12-16 |
Alexion Pharmaceuticals, Inc. |
De-immunized anti-CD3 antibody
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP2006380A4
(en)
|
2006-03-23 |
2010-08-11 |
Kyowa Hakko Kirin Co Ltd |
AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
|
|
US7608693B2
(en)
*
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
WO2009091240A1
(en)
|
2008-01-15 |
2009-07-23 |
Stichting Sanquin Bloedvoorziening |
Method and kits for detecting antibodies against therapeutic antibodies
|
|
NZ592611A
(en)
*
|
2008-10-10 |
2013-01-25 |
Emergent Product Dev Seattle |
A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
|
|
CA2741114A1
(en)
|
2008-10-24 |
2010-04-29 |
Cornelis Lammert Verweij |
Biomarkers for predicting the development of chronic autoimmune diseases
|
|
DE102008061522A1
(de)
|
2008-12-10 |
2010-06-17 |
Biontech Ag |
Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
|
|
WO2010122148A1
(en)
*
|
2009-04-24 |
2010-10-28 |
Boehringer Ingelheim International Gmbh |
An improved antibody domain and antibody fragments and antibodies based thereon
|
|
TWI507525B
(zh)
*
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
WO2011074965A1
(en)
|
2009-12-17 |
2011-06-23 |
Stichting Sanquin Bloedvoorziening |
Methods and means for counteracting an activity of an fc domain
|
|
JP2014518632A
(ja)
|
2011-06-01 |
2014-08-07 |
モアハウス スクール オブ メディスン |
ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
|
|
MY167125A
(en)
|
2011-08-17 |
2018-08-13 |
Glaxo Group Ltd |
Modified proteins and peptides
|
|
SG11201506451UA
(en)
|
2013-03-06 |
2015-09-29 |
Merrimack Pharmaceuticals Inc |
Anti-c-met tandem fc bispecific antibodies
|
|
TWI755763B
(zh)
*
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
IL315136A
(en)
*
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
WO2015187596A2
(en)
|
2014-06-02 |
2015-12-10 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
|
|
CN106999587B
(zh)
|
2014-10-02 |
2023-09-29 |
希望之城公司 |
多价中间表位，中间表位结合抗体及其用途
|
|
CN107076761B
(zh)
*
|
2014-11-05 |
2020-05-05 |
豪夫迈·罗氏有限公司 |
用于测定针对效应子功能抑制的人或人源化药物抗体的抗药物抗体的方法
|
|
CA3246946A1
(en)
*
|
2014-11-14 |
2025-11-29 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
EP4015533A1
(en)
*
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
|
WO2017075259A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibody formulations
|
|
EP3515944A4
(en)
*
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
|
|
TW201829463A
(zh)
*
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
PT3515465T
(pt)
*
|
2017-08-18 |
2024-03-04 |
Regeneron Pharma |
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
|
|
EP3713966A1
(en)
|
2017-11-22 |
2020-09-30 |
Vacara AB |
Antibodies to citrullinated proteins
|
|
MX2021000239A
(es)
|
2018-07-10 |
2021-03-25 |
Regeneron Pharma |
Modificacion de moleculas de union para minimizar interacciones preexistentes.
|
|
US20220244252A1
(en)
|
2019-06-07 |
2022-08-04 |
Sanquin Innovatie B.V. |
Methods and compounds for typing rheumatoid factors
|